Infection, Pulmonary Disease, Chronic Obstructive

Inclusion Criteria

- Adult subjects with COPD, 40 - 75 years of age
 - All subjects must have a diagnosis of COPD and must have airway obstruction with a post-bronchodilator Forced Expiratory Volume in 1 sec (FEV1) of >/= 30% and <= 80% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of </= 70% 
 - Subjects must be current or ex-smokers with a smoking history of more than 10 pack-years
 - Subjects must be able to perform technically acceptable pulmonary function tests during the study period as required in the protocol
 - Subjects must be able to produce an sufficient amount of sputum during sputum induction at screening

Exclusion Criteria

- Subjects with a significant respiratory disease other than COPD.
 - Exacerbation within 8 weeks prior to screening
 - Subjects with more than 1 COPD exacerbation within 12 months prior to screening
 - Subjects must have an FEV1 of at least one Liter 
 - Subjects with a history or physician’s diagnosis of asthma. If a patient has a total blood eosinophil count >/= 0.6 x 10^9/L source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition.
 - Subjects with hypersensitivity to the ciprofloxacin or to other quinolones and/or to inactive constituents of the inhalation powder
 - Subjects with known hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution
 - Subjects with a history of cystic fibrosis
 - Subjects with clinically evident bronchiectasis
 - Subjects taking any:
 -- Oral beta-adrenergic drugs or non cardioselective beta blockers,
 -- Oral glucocorticoids,
 -- Antihistamines or antileukotrienes prescribed for asthma,
 -- Oral cromolyn sodium or oral nedocromil sodium,
 -- Concomitant inhalative therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones